Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

7074.3;4 LSPP-LS

Projekttitel

Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Projekttitel Englisch

Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins
Abstract (Englisch)	Plants have been shown to be an economically viable alternative for the production of therapeutic recombinant proteins. A major obstacle is the non-human glycosylation pattern introduced by the plant N-glycosylation machinery, which can influence circulatory half-life, immunogenicity and biological activity. GlycArt Biotechnology¿s glycoengineering methods for mammalian cells will now be adapted to plants in collaboration with Dr. Kallio¿s group to engineer the plant cell glycosylation machinery to produce recombinant therapeutic glycoproteins with human-like carbohydrates.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Glycosylation Engineering of Plants for the Production of Novel Glycoengineered Therapeutic Proteins

Abstract
(Englisch)

Plants have been shown to be an economically viable alternative for the production of therapeutic recombinant proteins. A major obstacle is the non-human glycosylation pattern introduced by the plant N-glycosylation machinery, which can influence circulatory half-life, immunogenicity and biological activity. GlycArt Biotechnology¿s glycoengineering methods for mammalian cells will now be adapted to plants in collaboration with Dr. Kallio¿s group to engineer the plant cell glycosylation machinery to produce recombinant therapeutic glycoproteins with human-like carbohydrates.